Quick Takeaways
- Mikael Dolsten has 5 issuer positions tracked on this page.
- Estimated disclosed ownership value: $17,410,325.
- Recent insider filing activity is available below.
- Info
- Insider Ownership
Insider Trading & Ownership of Mikael Dolsten
- Location
- Santa Clara, CA
- Summary
- The estimated net worth of Mikael Dolsten is at least $17,410,325 dollars as of 23 Mar 2026. Mikael Dolsten is the President R&D of PFIZER INC and owns shares of PFIZER INC (PFE) stock worth about $15.24M. Mikael Dolsten is the Director of AGILENT TECHNOLOGIES, INC. and owns shares of AGILENT TECHNOLOGIES, INC. (A) stock worth about $890.3K. Mikael Dolsten is the Director of Apellis Pharmaceuticals, Inc. and owns shares of Apellis Pharmaceuticals, Inc. (APLS) stock worth about $821.4K. Mikael Dolsten is the Director of ROCKET PHARMACEUTICALS, INC. and owns shares of ROCKET PHARMACEUTICALS, INC. (RCKT) stock worth about $454.1K.
- Signature
- /s/ Shirley Qin, attorney-in-fact for Mr. Dolsten
- All Insider Reports
- All Insider Reports
Follow Filing Activity
Follow Mikael Dolsten and return when a new Insider Trading filing appears.
This tracks SEC filing changes for this page using existing product update flows.
What Changed
- Largest disclosed position: PFIZER INC ($15,244,495).
- Past-year value change for that position: .
Why This Matters
- This page translates Forms 3/4/5 into a quick ownership context before you inspect each transaction row.
- You can cross-check role, issuer, and filing chronology directly against the SEC source.
Official SEC Source
Filed on Form 4
Insider ownership context is sourced from SEC Forms 3, 4, and 5.
See Original FilingOwnership of Mikael Dolsten
| Symbol | Company | Relationship | Holdings Value | Past Year Net Change | Change % | Report Period |
|---|---|---|---|---|---|---|
| PFE | PFIZER INC | President R&D | $15,244,495 | 12 Sep 2024 | ||
| A | AGILENT TECHNOLOGIES, INC. | Director | $890,277 | -$389,511 | -30% | 19 Mar 2026 |
| APLS | Apellis Pharmaceuticals, Inc. | Director | $821,448 | 02 Mar 2026 | ||
| RCKT, RCKTW | ROCKET PHARMACEUTICALS, INC. | Director | $454,105 | 18 Jun 2025 | ||
| KPTI | Karyopharm Therapeutics Inc. | Director | 21 May 2021 |
Insider Transactions Reported by Mikael Dolsten:
| Sym | Company | Class | Transaction | % | Value $ | * Price $ | Shares | Shares After | Date | Ownership |
|---|
* An asterisk sign (*) next to the price indicates that the price is likely invalid.